skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreProduct loginProductLogin
Global Search Configuration

Roche's blockbuster cancer drug Avastin (bevacizumab) generated nearly $7bn in revenues in 2018, but Avastin's solid status on Roche's top line will be tested with the launch of the first biosimilar in the US. Allergan PLC and Amgen Inc. launched the first US biosimilar for Avastin and Roche's Herceptin (trastuzumab) on 18 July, marking the first oncology biosimilar launches in the US. 

It's unclear how the commercial dynamics will play out, but Scrip looked at the commercial and development history of Avastin since its first US FDA approval in 2004 for metastatic colon cancer. Avastin was a blockbuster in its first full year on the market. It rose to become Roche's top-selling drug in 2009 before losing that status in 2012 after a breast cancer indication was withdrawn. 

Scrip_A_New_Day_Dawns_For_Avastin

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Start a free trial

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact Sales

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now